The Europe Hemophilia Market should witness market growth of 5.7% CAGR during the forecast period (2023-2030).
The market is expanding as a result of a number of causes, including the rising prevalence of hemophilia, supportive government initiatives, and increased research and development for the creation of novel medicines. The growing target demographic, higher diagnostic rates, more people being diagnosed with the condition, and an increase in preventative therapy for hemophilia are all factors that support market expansion.
Due to the requirement for more clotting factors or a different type of clotting factor, treating bleeding episodes becomes incredibly challenging, and the expense of care for a person with an inhibitor can soar. Inhibitors frequently cause increased joint disease and other bleeding-related issues that lower the quality of life.
The European Commission has granted BioMarin's ROCTAVIANTM (valoctocogene roxaparvovec) gene therapy conditional marketing authorization for the management of severe hemophilia A. The therapyis specifically developed foradult patients that don't havea history of Factor VIII inhibitors and with no detectable antibodies to adeno-associated virus serotype 5 (AAV5). Additionally, the EC agreed with the European Medicines Agency's (EMA) proposal that Roctavian keep its orphan medicine status, allowing it a 10-year window of market exclusivity. Therefore, similar efforts and developments in the coming years will propel the market's growth.
The Germany market dominated the Europe Hemophilia Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,114.3 million by 2030. The UK market is exhibiting a CAGR of 4.8% during (2023-2030). Additionally, The France market would experience a CAGR of 6.5% during (2023-2030).
Based on Distribution Channel, the market is segmented into Specialty Pharmacies, and Hospital Pharmacies. Based on Type, the market is segmented into Hemophilia A, Hemophilia B, and Others. Based on Treatment Type, the market is segmented into Prophylaxis, On-demand, and Cure. Based on Therapy, the market is segmented into Factor Replacement Therapy (Recombinant Factor Concentrates, and Plasma-derived Factor Concentrates), Desmopressin & Fibrin Sealants, and Gene Therapy & Monoclonal Antibodies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, CSL Limited (CSL Behring), Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB (Investor AB) and Sanofi S.A.
The market is expanding as a result of a number of causes, including the rising prevalence of hemophilia, supportive government initiatives, and increased research and development for the creation of novel medicines. The growing target demographic, higher diagnostic rates, more people being diagnosed with the condition, and an increase in preventative therapy for hemophilia are all factors that support market expansion.
Due to the requirement for more clotting factors or a different type of clotting factor, treating bleeding episodes becomes incredibly challenging, and the expense of care for a person with an inhibitor can soar. Inhibitors frequently cause increased joint disease and other bleeding-related issues that lower the quality of life.
The European Commission has granted BioMarin's ROCTAVIANTM (valoctocogene roxaparvovec) gene therapy conditional marketing authorization for the management of severe hemophilia A. The therapyis specifically developed foradult patients that don't havea history of Factor VIII inhibitors and with no detectable antibodies to adeno-associated virus serotype 5 (AAV5). Additionally, the EC agreed with the European Medicines Agency's (EMA) proposal that Roctavian keep its orphan medicine status, allowing it a 10-year window of market exclusivity. Therefore, similar efforts and developments in the coming years will propel the market's growth.
The Germany market dominated the Europe Hemophilia Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,114.3 million by 2030. The UK market is exhibiting a CAGR of 4.8% during (2023-2030). Additionally, The France market would experience a CAGR of 6.5% during (2023-2030).
Based on Distribution Channel, the market is segmented into Specialty Pharmacies, and Hospital Pharmacies. Based on Type, the market is segmented into Hemophilia A, Hemophilia B, and Others. Based on Treatment Type, the market is segmented into Prophylaxis, On-demand, and Cure. Based on Therapy, the market is segmented into Factor Replacement Therapy (Recombinant Factor Concentrates, and Plasma-derived Factor Concentrates), Desmopressin & Fibrin Sealants, and Gene Therapy & Monoclonal Antibodies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, CSL Limited (CSL Behring), Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB (Investor AB) and Sanofi S.A.
Scope of the Study
By Distribution Channel
- Specialty Pharmacies
- Hospital Pharmacies
By Type
- Hemophilia A
- Hemophilia B
- Others
By Treatment Type
- Prophylaxis
- On-demand
- Cure
By Therapy
- Factor Replacement Therapy
- Recombinant Factor Concentrates
- Plasma-derived Factor Concentrates
- Desmopressin & Fibrin Sealants
- Gene Therapy & Monoclonal Antibodies
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Takeda Pharmaceutical Company Limited
- CSL Limited (CSL Behring)
- Pfizer, Inc.
- Bayer AG
- F.Hoffmann-La Roche Ltd.
- Novo Nordisk A/S
- Octapharma AG
- BioMarin Pharmaceutical Inc.
- Swedish Orphan Biovitrum AB (Investor AB)
- Sanofi S.A.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market At a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Europe Hemophilia Market by Distribution Channel
Chapter 6. Europe Hemophilia Market by Type
Chapter 7. Europe Hemophilia Market by Treatment Type
Chapter 8. Europe Hemophilia Market by Therapy
Chapter 9. Europe Hemophilia Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Takeda Pharmaceutical Company Limited
- CSL Limited (CSL Behring)
- Pfizer, Inc.
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Novo Nordisk A/S
- Octapharma AG
- BioMarin Pharmaceutical Inc.
- Swedish Orphan Biovitrum AB (Investor AB)
- Sanofi S.A.
Methodology
LOADING...
